ClinicalTrials.gg
WithdrawnNCT02130661Updated Dec 13, 2016

Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers

A Phase 1 interventional study of Rilapladib 25 mg and Rilapladib 250 mg in Alzheimer's Disease, sponsored by GlaxoSmithKline. Withdrawn. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-13.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Alzheimer Disease by GlaxoSmithKline — 2 open to participants now, 2 under way, none of them phase 3. Alzheimer Disease · GlaxoSmithKline.

Enrollment
33rd of 34
0 · median 120
Started
2017
the only one that year
Phase 1
14 of 34
none open now
Registered
31st of 34
by date

Among the 34 studies in Alzheimer Disease by GlaxoSmithKline, this one is the 33rd largest by enrollment, is the only one that started in 2017, is one of 14 in phase 1, and was the 31st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 34 studies in Alzheimer Disease by GlaxoSmithKline are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Alzheimer Disease by GlaxoSmithKline, or all of them as a file.
02

Study summary

Rilapladib is a potent and selective inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2), which was previously under development for the treatment of atherosclerosis and is currently being developed for the treatment of Alzheimer's disease.

This study is a single-center, open-label, two-part study. The two study parts will run independently. Subjects dosed in one part of this study will not be permitted to participate in the other part.

Part A will investigate the pharmacokinetic profile of rilapladib and its metabolites, SB-664601 and GSK1174379, after single dose and steady state dosing of rilapladib 250 milligram (mg) along with the biliary and urinary elimination pathways of rilapladib 250 mg. Part B will determine the effect of repeat administration of itraconazole on the PK of a single oral dose of rilapladib 25 mg.

Healthy male and female subjects, aged 18-65 years, will be recruited for this study. Ten subjects will be recruited for Part A and 20 subjects will be recruited for Part B.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • drug interaction
  • healthy volunteer
  • rilapladib
  • SB-659032
  • Alzheimer's disease
  • itraconazole
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged between 18 and 65 years of age inclusive, at the time of signing the .
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and (ECG). A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the Glaxosmithkline (GSK) Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • A subject with an (ALT), alkaline phosphatase or laboratory result outside the reference range may be included only if the Investigator and GSK Medical Monitor agree and document that the finding is unlikely to introduce additional risk factors.
  • A female subject is eligible to participate if she is of: Non- defined as pre-menopausal females with a documented tubal ligation or hysterectomy [for this definition, "documented" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records]; or defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli-International units/milliliter (MIU/mL) and estradiol \< 40 picogram (pg)/mL (\<147 picomole/Litre [pmol/L]) is confirmatory].
  • Body weight >= 50 kilogram (kg) and (BMI) within the range 19-32 kg/square meter (m\^2) (inclusive).
  • Based on single duration corrected for heart rate by Fridericia's formula (QTcF): QTcF \<450millisecond (msec); or QTcF \<480 msec in subjects with right bundle branch block.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion criteria

Exclusion Criteria:

Criteria Based Upon Medical History

  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), or prior cholecystectomy.
  • History of asthma, anaphylaxis or anaphylactoid reactions, or severe allergic responses.
  • Lifetime history of suicide attempt or active suicidal ideation within the past six months.
  • Current major depressive episode or a previous episode of depression requiring medical intervention.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia (if the clinical research unit uses heparin to maintain intravenous cannula patency).
  • History of sensitivity to compounds with a chemical structure related to rilapladib or itraconazole, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • Any for itraconazole administration.
  • Requiring the use of oral or injectable strong Cytochrome P450 3A4 () inhibitors or use of other CYP3A4 inhibitors/inducers within 14 days prior to dosing.
  • Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St. John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram (g) of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.

Criteria Based Upon Diagnostic Assessments

  • A positive pre-study surface antigen, positive antibody result, or positive test for (HIV) antibody.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • A positive pre-study drug or alcohol screen.

Other Criteria

  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Previous participation in this study.
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices within 7 days prior to the first dose of study medication until collection of the final pharmacokinetic sample.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part A

    Subjects will receive 250 mg of rilapladib once daily (QD) for 14 days (Days 1-14)

    Drug: Rilapladib 250 mg

  • Experimental
    Part B

    Subjects will receive 25 mg of rilapladib QD for 1 day (Day 1), 200 mg of itraconazole twice daily (BID) for 1 day (Day 8) and QD for 2 days (Days 9-10). Subjects will receive 25 mg of rilapladib + 200 mg of itraconazole for 1 day (Day 11) and 200 mg of itraconazole QD for 6 days (Day 12-17)

    Drug: Rilapladib 25 mg · Drug: Itraconazole

Interventions

  • White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.

  • White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.

  • 100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax), time of occurrence of Cmax (Tmax), area under the concentration-time curve over the dosing interval (AUC(0-Tau)) of rilapladib parent compound after single and repeat dosing, in part A of the study.

    Cmax, Tmax and AUC (0-Tau) will be used to evaluate the pharmacokinetics of rilapladib after single and repeat dosing of rilapladib 250 mg.

    Time frame: Day (D)1: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24 hours (hrs) post-dose, and D14: pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 32, 48 (D16), 96 (D18), 144 (D20), 240 (D24) and 336 (D28) hrs post-dose. Pre-dose on Days 11, 12 and 13

  2. Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)), and terminal phase half-life (T1/2) of rilapladib after repeat dosing, in part A of the study

    AUC(0-infinity) and T1/2 of rilapladib will be used to evaluate the pharmacokinetics of rilapladib and its metabolites after repeat dosing of rilapladib 250 mg.

    Time frame: D1: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24 hrs post-dose, and D14: pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 32, 48 (D16), 96 (D18), 144 (D20), 240 (D24) and 336 (D28) hrs post-dose. Pre-dose on Days 11, 12 and 13

  3. Cmax, Tmax, AUC(0-tau), and area under the concentration-time curve from time zero (pre-dose) to time of last quantifiable concentration (AUC(0-t)) of SB-664601 and GSK1174379 after single and repeat dosing, in part A of the study

    Cmax, Tmax, AUC(0-tau), and AUC(0-t) will be used to evaluate the pharmacokinetics of SB-664601 and GSK1174379 after single and repeat dosing of rilapladib 250 mg.

    Time frame: D1: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24 hrs post-dose, and D14: pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 32, 48 (D16), 96 (D18), 144 (D20), 240 (D24) and 336 (D28) hrs post-dose. Pre-dose on Days 11, 12 and 13

  4. AUC(0-infinity) and T1/2 of SB-664601 and GSK1174379 after repeat dosing, as data permit, in part A of the study.

    AUC(0-infinity) and T1/2 will be used to evaluate the pharmacokinetics of SB-664601 and GSK1174379 after repeat dosing of rilapladib 250 mg.

    Time frame: D1: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24 hrs post-dose, and D14: pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 32, 48 (D16), 96 (D18), 144 (D20), 240 (D24) and 336 (D28) hrs post-dose. Pre-dose on Days 11, 12 and 13

  5. AUC(0 infinity), AUC(0 t), and Cmax of rilapladib alone and in the presence of itraconazole in part B of the study.

    AUC(0 infinity), AUC(0 t), and Cmax will be used to evaluate the effect of repeat oral dosing of itraconazole on the pharmacokinetics of single dose rilapladib 25 mg.

    Time frame: D1 : Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 32, 48 (D3), 96 (D5), 144 (D7) hours post dose, and on D 11: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 32, 48 (D13), 96 (D15), 144 (D17) hours post dose

Secondary outcomes

  1. Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by adverse events (AEs), in part A of the study.

    AEs will be collected from the start of Study Treatment and until the follow-up

    Time frame: Up to Day 38

  2. Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by 12-lead electrocardiogram (ECG) parameters, in part A of the study.

    Single 12-lead ECGs will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures pulse rate (PR), QRS, QT, and QTcF intervals.

    Time frame: Up to Day 38

  3. Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by measuring vital signs, in part A of the study.

    Vital sign measurements will be performed in semi-supine or supine position after 10 minutes rest and will include systolic and diastolic blood pressure and pulse rate.

    Time frame: Up to Day 38

  4. Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by laboratory tests, in part A of the study.

    Laboratory tests will include haematology, clinical chemistry, urinalysis and additional parameters.

    Time frame: Up to Day 38

  5. Tmax and T1/2 of rilapladib alone and in the presence of itraconazole, in part B of the study.

    Tmax and T1/2 will be used to evaluate the effect of repeat oral dosing of itraconazole on the secondary PK parameters of rilapladib 25 mg.

    Time frame: D1 : Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 32, 48 (D3), 96 (D5), 144 (D7) hours post dose, and on D 11: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 32, 48 (D13), 96 (D15), 144 (D17) hours post dose

  6. AUC(0-infinity), AUC(0-t), Cmax, Tmax and T1/2 of rilapladib metabolites, SB-664601 and GSK1174379, alone and in the presence of itraconazole, in part B of the study.

    AUC(0-infinity), AUC(0-t), Cmax, Tmax and T1/2 will be used to evaluate the effect of repeat oral dosing of itraconazole on the PK of the rilapladib metabolites, SB-554601 and GSK1174379, after single dose of rilapladib 25 mg.

    Time frame: D1 : Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 32, 48 (D3), 96 (D5), 144 (D7) hours post dose, and on D 11: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 32, 48 (D13), 96 (D15), 144 (D17) hours post dose

  7. Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed by AEs, in part B of the study.

    AEs will be collected from the start of Study Treatment and until the follow-up

    Time frame: Up to Day 27

  8. Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed using ECG parameters, in part B of the study.

    Single 12-lead ECGs will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals.

    Time frame: Up to Day 27

  9. Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed as vital signs, in part B of the study.

    Vital sign measurements will be performed in semi-supine or supine position after 10 minutes rest and will include systolic and diastolic blood pressure and pulse rate.

    Time frame: Up to Day 27

  10. Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with itraconazole, assessed by laboratory tests, in part B of the study.

    Laboratory tests will include haematology, clinical chemistry, urinalysis and additional parameters.

    Time frame: Up to Day 27

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2017, a primary completion of Jan 2018 and a completion of Jan 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2014
First posted
May 5, 2014
Start
Oct 2017
Primary completionEst.
Jan 2018
CompletionEst.
Jan 2018
Last update
Dec 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02130661
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 5, 2014
Start date
Oct 2017
Primary completion
Jan 2018 (estimated)
Completion
Jan 2018 (estimated)
Last update
Dec 13, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rilapladib · Itraconazole

Start the discussion